Filter your results
- 2
- 2
- 2
- 1
- 1
- 2
- 1
- 1
- 1
- 1
- 1
- 1
- 2
- 2
- 2
- 2
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
|
|
sorted by
|
|
The Sec61 translocon is a therapeutic vulnerability in multiple myelomaEMBO Molecular Medicine, 2022, Online ahead of print., pp.e14740. ⟨10.15252/emmm.202114740⟩
Journal articles
pasteur-03534527v1
|
||
|
Sec61 blockade therapy overrides resistance to proteasome inhibitors and immunomodulatory drugs in multiple myelomaFrontiers in Oncology, 2023, 13, pp.1110916. ⟨10.3389/fonc.2023.1110916⟩
Journal articles
hal-04131407v1
|